Kaerus wins two FDA designations for KER-0193 in Fragile X syndrome

14 May 2025

UK-based Kaerus Bioscience, a biopharma created by European investment firm Medicxi for the development of therapeutics for rare genetic syndromes of neurodevelopment, has announced that its lead candidate KER-0193 has been granted both Orphan Drug designation and Rare Pediatric Drug designations for the treatment of Fragile X syndrome (FXS) by the US Food and Drugs Administration (FDA).

This follows the recent successful completion of a Phase I trial of KER-0193 in healthy volunteers, which confirmed the drug to be safe, well tolerated and exhibit excellent pharmacokinetics.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Company Spotlight



More Features in Biotechnology